Loading organizations...
§ Venture Capital · New York City, NY, USA
No information is available regarding this organization's activities, business model, or focus.
Kravis Investment Partners is an entity for which detailed operational information, including its primary activities and headquarters, is not publicly available. Public records do not disclose specific details regarding its business model, target sectors, or customer base, making it challenging to ascertain its market position or strategic focus within the investment landscape. Information concerning its scale, such as funding raised, assets under management (AUM), valuation, or employee count, is not readily identifiable in accessible databases. Furthermore, no recognizable lead investors, portfolio companies, or key customers are publicly associated with the organization, nor are there any reported GitHub stars or user counts. The founding year and names of its founders also remain undocumented in publicly available sources, preventing a comprehensive profile of the firm. This absence of verifiable data limits a full understanding of Kravis Investment Partners' operations and history.
Kravis Investment Partners has 4 tracked investments across 2 companies. The latest tracked deal is $270.0M Debt / Series C in Stashfin in June 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 21, 2022 | Stashfin | $270.0M Debt / Series C | — | Abstract Ventures, Altara Ventures, Fasanara Capital, Snow Leopard Technology Ventures, Tencent Holdings, Salil Deshpande |
| Apr 1, 2021 | Stashfin | $40.0M Series B | Uncorrelated Ventures, Altara Ventures | Accel, Bain Capital Ventures, Next47, Third Point Ventures, Venture Guides, Alto Partners, Integrated Capital, Positive Moves Consulting, Saison Capital, Snow Leopard Ventures, Tencent Cloud Europe |
| Feb 21, 2018 | ORIC Pharmaceuticals | $50.0M Series C | — | EcoR1 Capital, Fidelity Management & Research Company, Foresite Capital, Memorial Sloan Kettering Cancer Center, NS Investment, OrbiMed, Taiho Ventures, The Column Group, Topspin Fund, Trinitas Capital |
| Dec 2, 2015 | ORIC Pharmaceuticals | $53.0M Series B | — | EcoR1 Capital, Foresite Capital, Carl Gordon, Peter Svennilson, LEO Guthart |